GLYSURE PRESENTS SUCCESSFUL CLINICAL TRIAL RESULTS
AT ISICEM
Intensive Care trial data demonstrates accurate, continuous glucose readings
throughout the length of a patient’s stay in Intensive Care
Tuesday March 20, 2012: Oxfordshire, England: GlySure Limited, developer of in-hospital
continuous blood glucose monitoring systems, announced that Dr. Krishna Prasad is
presenting the results of its Intensive Care Unit (ICU) Pilot Trial for the first time at the 32nd
International Symposium on Intensive Care and Emergency Medicine (ISICEM) being held in
Brussels, Belgium from March 20th – 23rd, 2012.
The data show that the optical fluorescence sensor can successfully measure blood glucose
levels with a high degree of accuracy across a wide range of intensive care patients
throughout their length of stay in the ICU.
The pioneering new research results being presented at ISICEM were collected from
critically ill patients during GlySure’s recent pilot ICU clinical trial. It is the first major clinical
milestone for the venture capital backed medical technology company. GlySure believes its
continuous intravascular glucose monitoring system has the potential to improve outcomes
for over 8 million ICU patients annually.
At ISICEM Principal Investigator Dr Krishna Prasad will present the data from 18 ICU
patients with a broad range of conditions and co-morbidities including cardiac surgery,
cerebral trauma, sepsis, diabetes and hypertension. All of the critically ill patients were
monitored continuously and accurately for blood glucose levels throughout their length of
stay in the ICU – up to 100 hours of continuous monitoring.
“Clinicians have been waiting for a continuous real-time blood glucose monitor to support
implementation of Tight Glycemic Control protocols for much of the past decade,” said Dr.
Prasad. “Our study demonstrates that it is possible to monitor blood glucose levels
continuously and accurately throughout the length of stay of patients in the ICU.”
Commenting before the ISICEM presentation GlySure CEO Chris Jones said: “We are very
excited by the results of the pilot ICU clinical trial and are delighted to be able to share them
for the first time at ISICEM. We are looking forward to beginning our European and U.S.
clinical regulatory trials and bringing this technology to market to support clinicians in
realizing the promise of Tight Glycemic Control.”
GlySure’s presentation at ISICEM is entitled ‘Accuracy of a Continuous Intravascular
Glucose Monitor in ICU Patients’. An abstract will appear on the ISICEM website at the end
of the event.
###Ends###
Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235 462 870.
cjones@glysure.com
Media Contact: Bruce Dodworth, Sea Glass PR. Tel: +44 (0)1780 758555.
bruce@seaglasspr.com
Notes to Editors
About GlySure:
GlySure has developed a continuous intravascular glucose monitoring system using a
proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for
implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).
The company has demonstrated through ICU testing highly accurate sensors which can
provide continuous glucose readings throughout the length of a patient’s stay in the ICU.
GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20
employees. www.glysure.com
About Tight Glycemic Control (TGC):
In 2001 Greet Van den Berghe demonstrated that controlling patient glucose levels in the
ICU within tight normal ranges yielded significant improvements in patient outcomes
including a 46 per cent reduction in incidence of sepsis, 41 per cent reduction in renal failure,
50 per cent reduction in blood transfusions, and 34 per cent reduction in mortality. This
study created a new field of medical research with over 100 publications in the past decade
including two showing a financial benefit to the hospital in savings of $1,580 to €2,638 per
patient. The challenge for hospitals is that few ICU’s have the resources available to draw
blood and perform glucose measurements at the frequency required to safely maintain
patients within the target glucose range.
About ISICEM:
The International Symposium on Intensive Care and Emergency Medicine is organised
annually by the departments of Intensive Care and Emergency Medicine of Erasme
University Hospital, Université Libre de Bruxelles, in association with the Belgian Society of
Intensive Care and Emergency Medicine (SIZ). The objectives of this four-day symposium,
the largest of its kind worldwide, are to provide participants with a comprehensive, up-to-date
review of the most recent, clinically relevant developments in research, therapy, and
management of the critically ill. The meeting attracts more than 6,000 physicians, nurses
and other healthcare professionals interested in intensive care and emergency medicine and
a faculty of 200 well-known experts participate in the various session formats, including
lectures, workshops, round tables, 'meet the expert' sessions, pro/con debates, tutorials, and
demonstrations.